J&J's Pulmonary Push
J&J doubles disclosed respiratory pipeline in deals with RespiVert, Orexo
In a pair of deals last week, Johnson & Johnson doubled the number of compounds in its disclosed pipeline for respiratory diseases from four to eight, and it sounds like the pharma is still shopping.
J&J's Centocor Ortho Biotech Inc. unit acquired RespiVert Ltd., a private U.K. company with two lead compounds in preclinical development for asthma, chronic obstructive pulmonary disease (COPD) and cystic fibrosis (CF). Separately, Orexo AB granted J&J's Ortho-McNeil-Janssen Pharmaceuticals Inc. and Janssen Pharmaceutica N.V. subsidiaries exclusive, worldwide rights to develop and commercialize two compounds to treat asthma, COPD and other inflammatory conditions.